Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Background: Carbapenems (ertapenem, imipenem, meropenem) are used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB), even if the published evidence is limited, particularly when it is otherwise difficult to identify the recommended four active drugs to be inclu...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of molecular sciences Ročník 17; číslo 3; s. 373
Hlavní autoři:	Sotgiu, Giovanni, D’Ambrosio, Lia, Centis, Rosella, Tiberi, Simon, Esposito, Susanna, Dore, Simone, Spanevello, Antonio, Migliori, Giovanni
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI 12.03.2016
Témata:	Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use beta-Lactams - adverse effects beta-Lactams - therapeutic use Carbapenems - adverse effects Carbapenems - therapeutic use Clinical Studies as Topic Ertapenem Extensively Drug-Resistant Tuberculosis - drug therapy Humans Imipenem - adverse effects Imipenem - therapeutic use Meropenem Mycobacterium Review Thienamycins - adverse effects Thienamycins - therapeutic use Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy effectiveness imipenem safety tolerability meropenem MDR-TB carbapenems XDR-TB ertapenem
ISSN:	1422-0067, 1422-0067
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!